Helpful Treatments Keep People With Arthritis

hat if joint pain and stiffness are inevitable if youthe ongoing assessment of the safety of a product
don't take the medication, yet heart problems couldonce it is in widespread use."
occur if you do? Health officials say that, as with anyOthers Weigh In
drug, only you and your doctor can determine theThe concerns with the safety of so many pain
level of risk that is acceptable with medicationsrelievers used to treat arthritis underscores the
currently available to treat arthritis.importance of arthritis as a major health care issue in
The unsettling news in late 2004 that the popularthe United States. Arthritis experts, patient advocacy
anti-inflammatory arthritis drugs Vioxx (rofecoxib),groups, and other health organizations also are
Celebrex (celecoxib), and Bextra (valdecoxib) couldweighing in on the uncertainty of NSAIDs, and are
cause a heart attack or stroke or aggravate highrecognizing the need for developing new and safer
blood pressure has left some patients wonderingmedications.
whether they should keep taking them.The American College of Rheumatology is advising
Data from clinical trials showed thatphysicians to follow current treatment guidelines and
cyclooxygenase-2 selective agents, better known asmanufacturers' dosage recommendations for NSAIDs.
COX-2 inhibitors, may be associated with anTreatment guidelines exist to help doctors choose
increased risk of serious cardiovascular problems,the best options for their patients, based on current
especially when used in high doses or for long periodsscientific studies.
in patients with existing cardiovascular disease, or inThe Arthritis Foundation said in a statement that the
very high-risk situations, such as immediately afterfindings about the drugs should not have any
heart surgery. COX-2 inhibitors are the newestimmediate impact on the clinical use of them.
subset of non-steroidal anti-inflammatory drugs"Non-steroidal anti-inflammatory drugs continue to
(NSAIDs). COX-2 inhibitors were developedplay an important role in the management of arthritis
specifically to decrease the well-recognized gastricpain," says John H. Klippel, M.D., president and CEO of
side effects and intolerance associated with the usethe Arthritis Foundation. "Patients who derive benefit
of some NSAIDs.from these drugs should remain on their treatment
Traditional NSAIDs, such as aspirin or ibuprofen, actregimen, and discuss concerns with their physicians,"
by blocking the production of a family of chemicalshe says.
known as prostaglandins, which are not onlyBut Charles A. Birbara, M.D., a rheumatologist and
important in the development of inflammation, butassociate professor of medicine at the University of
also play an important role in maintaining the integrityMassachusetts Medical School in Worcester, Mass.,
of the stomach lining. At least two enzymes aresays that he has prescribed COX inhibitors cautiously
involved in this inflammation, namelyin older people or those with cardiovascular or renal
cyclooxygenase-1 (COX-1) and cyclooxygenase-2disease ever since early clinical studies discovered a
(COX-2). Traditional NSAIDs inhibit both COX-1 andpossible risk in this patient population.
COX-2. Unfortunately, this non-selective inhibition of"I'm not always willing to take a risk with my
both COX enzymes also inhibits those prostaglandinspatients, because we clearly don't have a complete
involved in some of the important "housekeeping"understanding of all the potential clinical issues
functions of the body, such as helping blood to clotassociated with use of these drugs," he says. Even
and protecting the stomach from ulceration.before the controversy, Birbara notes that the
It is this non-selective inhibition of both enzymes bylong-term effects of COX-2 agents were unknown.
aspirin and other non-selective NSAIDs that increasesBesides, he says, there are other treatment options
the risk of stomach ulcers and consequent bleeding.available that are equally effective.
In theory, the newer COX-2 selective inhibitors only"There are so many wonderful things happening with
inhibit the enzyme involved in inflammation, leavingrespect to current therapies of arthritis," he says.
the other functions alone."Clearly, we are so much better able to control
But Sandra Kweder, M.D., deputy director of theinflammatory arthritis with new biologic agents."
Food and Drug Administration's Office of New Drugs,Birbara adds that so many people whose lives were
says that new studies have had a surprising twist.diminished by joint disease can now look forward to
"The downside of the COX-2 selective inhibitors isan unrestricted lifestyle, which was "not even
that they appear to be associated--particularly whenimaginable just a few short years ago."
used for many consecutive months to years--with anRichard Shirley, 64, an avid birdwatcher from
increased risk of cardiovascular problems," she says.Wrentham, Mass., battled rheumatoid arthritis in
Moreover, COX-2 inhibitors, like other NSAIDs, don'tnearly every joint in his body for more than 25 years
influence the course of the disease--which doctorsbefore he saw Birbara. He couldn't button his shirt
say is a common misconception amongcuffs, walk frontward down a flight of stairs, or get
patients--because these drugs only provide forin and out of a car without a struggle. At times, his
symptom relief.hands were so swollen he couldn't grasp small
Coincidentally, preliminary results from a three-yearobjects or make a closed fist. Shirley had his wedding
trial on the non-selective NSAID Aleve (naproxen)ring resized so it would fit.
also suggested that long-term use may be associated"Richard had seen a number of physicians and had
with an increased risk for cardiovascular problems.been on many medications to treat his disease,"
Since the results of studies on both non-selective andBirbara says. "However, the aggressive nature of his
selective NSAIDs are preliminary and conflict witharthritis was not very responsive to standard
data from earlier studies of the same drugs, the FDAmedications." According to Birbara, X-rays of Shirley
issued a public health advisory in December 2004also showed evidence of joint destruction.
concerning use of all NSAIDs, pending further review"Doctor Birbara has a zero tolerance for hot and
of data that continue to be collected. The agencyinflamed joints," Shirley says, "because that's when
has recommended, among other things, thatthe damage is done." Shirley also believes, from his
physicians limit the use of COX-2 inhibitors untilown experience, that each person needs to work
further review.with his or her physician to find the appropriate
"Monitoring the drug safety of marketed productsmedicine. For him, a new biologic product made the
requires close collaboration between our clinicaldifference.
reviewers and drug safety staff to evaluate andFinding the right treatments for those at greatest
respond to adverse events identified in ongoing clinicalrisk for the potential complications of arthritis and
trials or reported to us by physicians and theirother rheumatic conditions, Birbara says, hopefully will
patients," says Kweder. "The most recent actionslessen the burden of this disease, not only in the
concerning [NSAIDs] illustrate the vital importance ofUnited States, but for the entire world.